{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:59:53Z","timestamp":1790769593698,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.leukres.2025.108121","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:21:03Z","timestamp":1760278863000},"page":"108121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The role of interim bone marrow assessments in acute myeloid leukemia \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5472-608X","authenticated-orcid":false,"given":"Yuanli","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Khawandanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Asch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-1608","authenticated-orcid":false,"given":"Zimu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.108121_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2013.091819","article-title":"Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group","volume":"99","author":"Bertoli","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2025.108121_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u2018intense\u2019 induction regimens: a report from SWOG and MD anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.108121_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","article-title":"A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML","volume":"38","author":"Garcia-Manero","year":"2024","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.leukres.2025.108121_bib4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"26","key":"10.1016\/j.leukres.2025.108121_bib5","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"S2","key":"10.1016\/j.leukres.2025.108121_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/1097-0142(197808)42:2+<874::AID-CNCR2820420709>3.0.CO;2-O","article-title":"Therapy of acute myelogenous leukemia","volume":"42","author":"Freireich","year":"1978","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2025.108121_bib7","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a southwest oncology group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2025.108121_bib8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood.V124.21.1004.1004","article-title":"Clinical utility of morphological evaluation of day 14 bone marrow biopsies in acute myeloid leukemia patients undergoing standard induction chemotherapy: time to change practice?","volume":"124","author":"Deutsch","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2025.108121_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.21133","article-title":"Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia","volume":"83","author":"Hussein","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.108121_bib10","first-page":"421","article-title":"G. Impact of day 14 bone marrow biopsy on Re-Induction decisions and prediction of a complete response in acute myeloid leukemia cases","volume":"19","author":"Alsaleh","year":"2018","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.leukres.2025.108121_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2012.09.016","article-title":"Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia","volume":"37","author":"Morris","year":"2013","journal-title":"Leuk. Res"},{"issue":"6","key":"10.1016\/j.leukres.2025.108121_bib12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2025.108121_bib13","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Acute Myeloid Leukemia Version 3.2024. NCCN. Accessed December 5, 2024. \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411\u3009."},{"issue":"4","key":"10.1016\/j.leukres.2025.108121_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12185-018-2478-3","article-title":"Re-induction chemotherapy using FLAG\u2013mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates","volume":"108","author":"Hassan","year":"2018","journal-title":"Int J. Hematol."},{"key":"10.1016\/j.leukres.2025.108121_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106731","article-title":"Re-induction therapy in adult patients with acute myeloid leukemia with \u226420% blasts: a retrospective cohort study","volume":"111","author":"Kannan","year":"2021","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.leukres.2025.108121_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clml.2018.11.001","article-title":"Comparison of peripheral blast clearance and day 14 bone marrow biopsy in predicting remission status and survival after 7+3 induction in acute myeloid leukemia","volume":"19","author":"Covut","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2025.108121_bib17","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/j.clml.2019.03.024","article-title":"Prognostic and therapeutic value of day 14 bone marrow aspiration in adult acute myeloid leukemia patients","volume":"19","author":"El Gammal","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib18","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41375-018-0268-9","article-title":"Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia\u2014a phase 3 study","volume":"32","author":"Braess","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2025.108121_bib19","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1182\/blood.V126.23.4974.4974","article-title":"The role of day 14 bone marrow analysis in determining leukemia free survival and overall survival","volume":"126","author":"Ollila","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108121_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/leu.2014.268","article-title":"Value of routine \u201cday 14\u201d marrow exam in newly diagnosed AML","volume":"29","author":"Yezefski","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2025.108121_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24271","article-title":"Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: can we do better?","volume":"91","author":"Campuzano-Zuluaga","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2025.108121_bib22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J. Clin. Epidemiol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-149-12-200812160-00008","article-title":"Systematic reviews of diagnostic test accuracy","volume":"149","author":"Leeflang","year":"2008","journal-title":"Ann. Intern Med"},{"issue":"1","key":"10.1016\/j.leukres.2025.108121_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2019.09.613","article-title":"Observation versus immediate reinduction for acute myeloid leukemia patients with indeterminate day 14 bone marrow results","volume":"20","author":"Jamy","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2025.108121_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML cooperative group (AMLCG) 1992 trial","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2025.108121_bib26","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cncr.25263","article-title":"Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the eastern cooperative oncology group","volume":"116","author":"Rowe","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.leukres.2025.108121_bib27","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood.V122.21.3924.3924","article-title":"Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens: a report from SWOG and Cleveland clinic","volume":"122","author":"Othus","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.108121_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbmt.2014.10.025","article-title":"Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy","volume":"21","author":"Othus","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.108121_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","article-title":"Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study","volume":"60","author":"Yates","year":"1982","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2025.108121_bib31","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.1996.14.7.2150","article-title":"Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the european organization for research and treatment of cancer leukemia cooperative group","volume":"14","author":"Zittoun","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.108121_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2025.108121_bib33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00277-004-0853-z","article-title":"Risk-adapted induction and consolidation therapy in adults with de novo AML aged \u2264 60 years: results of a prospective multicenter trial","volume":"83","author":"Heil","year":"2004","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib34","first-page":"1285","article-title":"Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia","volume":"85","author":"Liso","year":"2000","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.24207","article-title":"Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the \u201c3\u2009+\u20097\u201d induction regimen for acute myeloid leukemia","volume":"90","author":"Ofran","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108121_bib36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2025.108121_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-Internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.108121_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025016726","article-title":"Utility of IDH1\/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia","author":"Boertjes","year":"2025","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.leukres.2025.108121_bib39","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1002\/cncr.27494","article-title":"Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia","volume":"118","author":"Arellano","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2025.108121_bib40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3760\/cma.j.issn.0366-6999.20132107","article-title":"The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia","volume":"127","author":"Gao","year":"2014","journal-title":"Chin. Med J. (Engl. )"},{"issue":"7","key":"10.1016\/j.leukres.2025.108121_bib41","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.leukres.2025.108121_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3324\/haematol.2017.178442","article-title":"A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia","volume":"103","author":"Herold","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2025.108121_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/leu.2014.242","article-title":"Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD anderson cancer center","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib44","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML cooperative group","volume":"93","author":"B\u00fcchner","year":"1999","journal-title":"Blood"},{"issue":"ement_1","key":"10.1016\/j.leukres.2025.108121_bib45","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2019-127623","article-title":"Induction related mortality in acute myeloid leukemia: multivariate model of predictive score from the Indian acute leukemia research database (INwARD) of the hematology cancer consortium (HCC)","volume":"134","author":"Kayal","year":"2019","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.leukres.2025.108121_bib46","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.20.01392","article-title":"Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other High-Grade myeloid neoplasm","volume":"38","author":"Palmieri","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108121_bib47","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1182\/blood-2001-12-0354","article-title":"Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a southwest oncology group study","volume":"100","author":"Anderson","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2025.108121_bib48","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","article-title":"A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a southwest oncology group study (9031)","volume":"91","author":"Godwin","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2025.108121_bib49","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a southwest oncology group study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2025.108121_bib50","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"ement 1","key":"10.1016\/j.leukres.2025.108121_bib51","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1182\/blood-2022-165982","article-title":"Clinical outcome and Treatment-Related mortality in patients with acute myeloid leukemia treated at the Uganda cancer institute","volume":"140","author":"Okello","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2025.108121_bib52","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/j.clml.2019.03.024","article-title":"Prognostic and therapeutic value of day 14 bone marrow aspiration in adult acute myeloid leukemia patients","volume":"19","author":"El Gammal","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.108121_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106902","article-title":"Re-induction versus salvage for D14-resiudal acute myeloid leukemia: a retrospective multi-center study","volume":"119","author":"Frisch","year":"2022","journal-title":"Leuk. Res"},{"issue":"23","key":"10.1016\/j.leukres.2025.108121_bib54","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood.V126.23.4496.4496","article-title":"Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: results of a prospective electronic Patient-Reported outcomes study","volume":"126","author":"LeBlanc","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108121_bib55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.leukres.2018.09.014","article-title":"Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow","volume":"74","author":"Jamy","year":"2018","journal-title":"Leuk. Res"},{"issue":"10","key":"10.1016\/j.leukres.2025.108121_bib56","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ajh.27429","article-title":"Evaluating the role of day 14 bone marrow biopsy and european LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia","volume":"99","author":"Balev","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108121_bib57","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1080\/10428194.2018.1543878","article-title":"A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia","volume":"60","author":"Refaei","year":"2019","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:23:54Z","timestamp":1763645034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"alternative-id":["S0145212625006113"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108121","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interim bone marrow assessments in acute myeloid leukemia \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108121"}}